LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Role of macrophages and their exosomes in orthopedic diseases.

    Yuan, Riming / Li, Jianjun

    PeerJ

    2024  Volume 12, Page(s) e17146

    Abstract: Exosomes are vesicles with a lipid bilayer structure that carry various active substances, such as proteins, DNA, non-coding RNA, and nucleic acids; these participate in the immune response, tissue formation, and cell communication. Owing to their low ... ...

    Abstract Exosomes are vesicles with a lipid bilayer structure that carry various active substances, such as proteins, DNA, non-coding RNA, and nucleic acids; these participate in the immune response, tissue formation, and cell communication. Owing to their low immunogenicity, exosomes play a key role in regulating the skeletal immune environment. Macrophages are important immune cells that swallow various cellular and tissue fragments. M1-like and M2-like macrophages differentiate to play pro-inflammatory, anti-inflammatory, and repair roles following stimulation. In recent years, the increase in the population base and the aging of the population have led to a gradual rise in orthopedic diseases, placing a heavy burden on the social medical system and making it urgent to find effective solutions. Macrophages and their exosomes have been demonstrated to be closely associated with the pathogenesis and prognosis of orthopedic diseases. An in-depth understanding of their mechanisms of action and the interaction between them will be helpful for the future clinical treatment of orthopedic diseases. This review focuses on the mechanisms of action, diagnosis, and treatment of orthopedic diseases involving macrophages and their exosomes, including fracture healing, diabetic bone damage, osteosarcoma, and rheumatoid arthritis. In addition, we discuss the prospects and major challenges faced by macrophages and their exosomes in clinical practice.
    MeSH term(s) Humans ; Exosomes ; Macrophages ; Arthritis, Rheumatoid/metabolism ; Cell Communication
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 2703241-3
    ISSN 2167-8359 ; 2167-8359
    ISSN (online) 2167-8359
    ISSN 2167-8359
    DOI 10.7717/peerj.17146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: A uPAR targeted nanoplatform with an NIR laser-responsive drug release property for tri-modal imaging and synergistic photothermal-chemotherapy of triple-negative breast cancer

    Yu, Siming / Chen, Tianfeng / Huang, Guanning / Yuan, Riming

    Biomaterials science. 2020 Jan. 21, v. 8, no. 2

    2020  

    Abstract: In the present work, an iridium (Ir) complex loaded theranostic nanoplatform was designed for high-efficiency triple-negative breast cancer (TNBC) therapy. For this purpose, the Ir complex was firstly loaded on a photothermal agent of gold nanostars (GNS) ...

    Abstract In the present work, an iridium (Ir) complex loaded theranostic nanoplatform was designed for high-efficiency triple-negative breast cancer (TNBC) therapy. For this purpose, the Ir complex was firstly loaded on a photothermal agent of gold nanostars (GNS) by simply mixing followed by functionalization using a urokinase-type plasminogen activator receptor (uPAR) targeted polyetherimide-AE105 peptide conjugate (P-AE105) with the formation of GNS@Ir@P-AE105. It was demonstrated that the resultant GNS@Ir@P-AE105 was a multifunctional nanoplatform with advantages of (1) NIR laser controlled release of the Ir complex; (2) precise delivery of the Ir complex to TNBC cells; (3) excellent photothermal (PT)/photoacoustic (PA)/X-ray computed tomography (CT) tri-modal imaging ability; and (4) a synergistic photothermal-chemotherapeutic effect. An in-depth investigation of the mechanism revealed that binding forces of the Ir complex–GNS and P-AE105–GNS were significantly diminished upon NIR laser irradiation, which conferred an NIR laser-responsive Ir complex release property to the nanoplatform. Moreover, the nanoplatform exerted high efficiency anti-TNBC effects via a ROS-induced p53 apoptotic pathway. Specifically, combinational photothermal-chemotherapeutic treatments stimulated intracellular ROS generation, which significantly up-regulated apoptotic-relative p53 gene expression either by causing severe DNA damage or inducing an arrest effect on the sub-G1 phase of the cell cycle. Taken together, our work provides a novel theranostic nanoplatform for efficient and simultaneous diagnosis and therapy of TNBC.
    Keywords apoptosis ; breast neoplasms ; cell cycle ; computed tomography ; DNA damage ; drugs ; gene expression ; gene expression regulation ; gold ; image analysis ; iridium ; irradiation ; nanogold ; near infrared radiation ; peptides ; therapeutics ; u-plasminogen activator
    Language English
    Dates of publication 2020-0121
    Size p. 720-738.
    Publishing place The Royal Society of Chemistry
    Document type Article
    ZDB-ID 2693928-9
    ISSN 2047-4849 ; 2047-4830
    ISSN (online) 2047-4849
    ISSN 2047-4830
    DOI 10.1039/c9bm01495k
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  3. Article ; Online: A uPAR targeted nanoplatform with an NIR laser-responsive drug release property for tri-modal imaging and synergistic photothermal-chemotherapy of triple-negative breast cancer.

    Yu, Siming / Huang, Guanning / Yuan, Riming / Chen, Tianfeng

    Biomaterials science

    2019  Volume 8, Issue 2, Page(s) 720–738

    Abstract: In the present work, an iridium (Ir) complex loaded theranostic nanoplatform was designed for high-efficiency triple-negative breast cancer (TNBC) therapy. For this purpose, the Ir complex was firstly loaded on a photothermal agent of gold nanostars (GNS) ...

    Abstract In the present work, an iridium (Ir) complex loaded theranostic nanoplatform was designed for high-efficiency triple-negative breast cancer (TNBC) therapy. For this purpose, the Ir complex was firstly loaded on a photothermal agent of gold nanostars (GNS) by simply mixing followed by functionalization using a urokinase-type plasminogen activator receptor (uPAR) targeted polyetherimide-AE105 peptide conjugate (P-AE105) with the formation of GNS@Ir@P-AE105. It was demonstrated that the resultant GNS@Ir@P-AE105 was a multifunctional nanoplatform with advantages of (1) NIR laser controlled release of the Ir complex; (2) precise delivery of the Ir complex to TNBC cells; (3) excellent photothermal (PT)/photoacoustic (PA)/X-ray computed tomography (CT) tri-modal imaging ability; and (4) a synergistic photothermal-chemotherapeutic effect. An in-depth investigation of the mechanism revealed that binding forces of the Ir complex-GNS and P-AE105-GNS were significantly diminished upon NIR laser irradiation, which conferred an NIR laser-responsive Ir complex release property to the nanoplatform. Moreover, the nanoplatform exerted high efficiency anti-TNBC effects via a ROS-induced p53 apoptotic pathway. Specifically, combinational photothermal-chemotherapeutic treatments stimulated intracellular ROS generation, which significantly up-regulated apoptotic-relative p53 gene expression either by causing severe DNA damage or inducing an arrest effect on the sub-G1 phase of the cell cycle. Taken together, our work provides a novel theranostic nanoplatform for efficient and simultaneous diagnosis and therapy of TNBC.
    MeSH term(s) Animals ; Antineoplastic Agents/pharmacology ; Cell Proliferation/drug effects ; Combined Modality Therapy ; Drug Liberation ; Humans ; Infrared Rays ; Lasers ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Multimodal Imaging ; Optical Imaging ; Phototherapy ; Receptors, Urokinase Plasminogen Activator/antagonists & inhibitors ; Receptors, Urokinase Plasminogen Activator/metabolism ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/therapy ; Tumor Cells, Cultured
    Chemical Substances Antineoplastic Agents ; Receptors, Urokinase Plasminogen Activator
    Language English
    Publishing date 2019-11-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2693928-9
    ISSN 2047-4849 ; 2047-4830
    ISSN (online) 2047-4849
    ISSN 2047-4830
    DOI 10.1039/c9bm01495k
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer.

    Yuan, Riming / Huang, Yanyu / Chan, Leung / He, Dihao / Chen, Tianfeng

    ACS applied materials & interfaces

    2020  Volume 12, Issue 41, Page(s) 45714–45727

    Abstract: Despite the effective targeting of the epidermal growth factor receptor (EGFR), the use of gefitinib (GFT) for nonsmall cell lung cancer (NSCLC) treatment meets a failure because of the insufficient drug accumulation in the tumor region. Therefore, ... ...

    Abstract Despite the effective targeting of the epidermal growth factor receptor (EGFR), the use of gefitinib (GFT) for nonsmall cell lung cancer (NSCLC) treatment meets a failure because of the insufficient drug accumulation in the tumor region. Therefore, developing chemosensitizers of GFT with synergistic therapeutic effects is urgently needed for advanced cancer therapy. Herein, a natural chemosensitizer, natural borneol (NB), is reformulated as an oil-in-water nanoemulsion to enhance its solubility, distribution, and to ultimately increase the therapeutic index with GFT. The nanolization of NB (NBNPs) displays stronger targeted delivery and cytotoxicity than NB by selectively identifying eight specific protein targets in A549 NSCLC cells as revealed by the proteomic studies. Consistently, NBNPs realize stronger chemosensitization effects than NB with GFT by effectively regulating EGFR/EHD1-mediated apoptosis in A549 NSCLC cells. Owing to the satisfying synergistic effect between NBNPs and GFT, the combined therapy not only enhances the anticancer ability of GFT against NSCLC proliferation but also avoids heavy double toxicity in vivo. This finding demonstrates the effective synergism between NBNPs and GFT with clear mechanistic investigation and is expected to extend the application of NBNPs as a novel chemosensitizer for advanced cancer chemotherapy.
    MeSH term(s) Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Camphanes/chemistry ; Camphanes/pharmacology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Proliferation/drug effects ; Cells, Cultured ; Drug Screening Assays, Antitumor ; Emulsions/chemistry ; Female ; Gefitinib/chemistry ; Gefitinib/pharmacology ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Molecular Structure ; Nanoparticles/chemistry ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Particle Size ; Surface Properties ; Vesicular Transport Proteins/antagonists & inhibitors ; Vesicular Transport Proteins/metabolism
    Chemical Substances Antineoplastic Agents ; Camphanes ; EHD1 protein, human ; Emulsions ; Vesicular Transport Proteins ; isoborneol (L88RA8N5EG) ; Gefitinib (S65743JHBS)
    Language English
    Publishing date 2020-10-05
    Publishing country United States
    Document type Journal Article
    ISSN 1944-8252
    ISSN (online) 1944-8252
    DOI 10.1021/acsami.0c08069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer

    Yuan, Riming / Huang, Yanyu / Chan, Leung / He, Dihao / Chen, Tianfeng

    ACS applied materials & interfaces. 2020 Sept. 15, v. 12, no. 41

    2020  

    Abstract: Despite the effective targeting of the epidermal growth factor receptor (EGFR), the use of gefitinib (GFT) for nonsmall cell lung cancer (NSCLC) treatment meets a failure because of the insufficient drug accumulation in the tumor region. Therefore, ... ...

    Abstract Despite the effective targeting of the epidermal growth factor receptor (EGFR), the use of gefitinib (GFT) for nonsmall cell lung cancer (NSCLC) treatment meets a failure because of the insufficient drug accumulation in the tumor region. Therefore, developing chemosensitizers of GFT with synergistic therapeutic effects is urgently needed for advanced cancer therapy. Herein, a natural chemosensitizer, natural borneol (NB), is reformulated as an oil-in-water nanoemulsion to enhance its solubility, distribution, and to ultimately increase the therapeutic index with GFT. The nanolization of NB (NBNPs) displays stronger targeted delivery and cytotoxicity than NB by selectively identifying eight specific protein targets in A549 NSCLC cells as revealed by the proteomic studies. Consistently, NBNPs realize stronger chemosensitization effects than NB with GFT by effectively regulating EGFR/EHD1-mediated apoptosis in A549 NSCLC cells. Owing to the satisfying synergistic effect between NBNPs and GFT, the combined therapy not only enhances the anticancer ability of GFT against NSCLC proliferation but also avoids heavy double toxicity in vivo. This finding demonstrates the effective synergism between NBNPs and GFT with clear mechanistic investigation and is expected to extend the application of NBNPs as a novel chemosensitizer for advanced cancer chemotherapy.
    Keywords apoptosis ; borneol ; cancer therapy ; chemosensitization ; cytotoxicity ; drug therapy ; drugs ; epidermal growth factor receptors ; lung neoplasms ; nanoemulsions ; proteomics ; solubility ; synergism
    Language English
    Dates of publication 2020-0915
    Size p. 45714-45727.
    Publishing place American Chemical Society
    Document type Article
    Note NAL-AP-2-clean
    ISSN 1944-8252
    DOI 10.1021/acsami.0c08069
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article: [Change of early serum TNF-alpha and IL-6 levels in acute cerebral infarction and its significances].

    Lin, Jiu-zuo / Miao, Ke-qiang / Zhang, Hai-xia / Kong, Qing-zuan / Yuan, Ri-ming / Wang, Zhen-wei / Liu, Shun-xiang

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

    2010  Volume 39, Issue 4, Page(s) 415–418

    Abstract: Objective: To investigate the change of early serum TNF-alpha and IL-6 levels in acute cerebral infarction and its significances.: Methods: Serum TNF-alpha and IL-6 levels in 30 health subjects and 35 patients with acute cerebral infarction (ACI) ... ...

    Abstract Objective: To investigate the change of early serum TNF-alpha and IL-6 levels in acute cerebral infarction and its significances.
    Methods: Serum TNF-alpha and IL-6 levels in 30 health subjects and 35 patients with acute cerebral infarction (ACI) within 6 hours of onset were measured by enzyme linked immunosorbent assay (ELISA); neurological deficits scores (NDS) in all cases were determined, and Spearman test was used for correlation.
    Results: The serum levels of TNF-alpha and IL-6 in ACI group were markedly higher than those in health subjects and there was a positive correlation of TNF-alpha and IL-6 levels with 6 h NDS (rs=0.89 and 0.93, P<0.001) and with NDS progression (rs=0.90 and 0.91, P<0.001). Early serum TNF-alpha and IL-6 levels in progressive cerebral infarction (PCI) group were evidently higher than those in stable cerebral infarction (SCI)[(49.56+/-12.12) pg/L compared with (24.30+/-7.4) ng/L and (39.76+/-7.88) ng/L compared with (20.78+/-6.28) ng/L, respectively, P<0.01)].
    Conclusion: The early serum levels of TNF-alpha and IL-6 in ACI markedly increase and are closely correlated with disease severity; which may be of value in PCI risk evaluation.
    MeSH term(s) Acute Disease ; Adult ; Aged ; Biomarkers/blood ; Cerebral Infarction/blood ; Early Diagnosis ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Interleukin-6/blood ; Male ; Middle Aged ; Time Factors ; Tumor Necrosis Factor-alpha/blood
    Chemical Substances Biomarkers ; IL6 protein, human ; Interleukin-6 ; Tumor Necrosis Factor-alpha
    Language Chinese
    Publishing date 2010
    Publishing country China
    Document type English Abstract ; Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1008-9292
    ISSN 1008-9292
    DOI 10.3785/j.issn.1008-9292.2010.04.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top